



Achillion Pharmaceuticals  
 Investor Relations Department  
 300 George St.  
 New Haven, CT 06511  
 United States

Visit IR website [↗](#)  
 Sign-up for Email alerts [↗](#)

**NASDAQ: ACHN**

|               |                            |
|---------------|----------------------------|
| Last Trade:   | 2.99                       |
| Trade Time:   | 3:59 PM ET<br>Jan 19, 2018 |
| Change:       | 0.00 (0.000%)              |
| Day Range     | N/A - N/A                  |
| 52-Week Range | 2.69 - 5.66                |
| Volume        | N/A                        |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

**Company Profile**


Rooted in the myth of Achilles, the name of Achillion refers to the brave warrior committed to a cause as well as the company's mission to combat diseases by identifying and exploiting their unique vulnerabilities.

**Inspiring Science. Innovative Medicine.**

Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is a science-driven, patient-focused company leveraging its strengths across the continuum from drug discovery to commercialization to provide better treatments for people with serious diseases.

... [\(more\)](#)

**Stock Performance**



**Press Releases** [ View all ]

- Dec 20, 2017*  
[Achillion Initiates Phase I First-In-Human Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D](#)
- Dec 18, 2017*  
[Achillion Announces ACH-4471 Granted Orphan Drug Designation for the Treatment of C3 Glomerulopathy \(C3G\) and the Initiation of a Phase 1 Extended-Release Bioavailability Study](#)
- Nov 15, 2017*  
[Achillion Announces Pricing of Secondary Offering Of Common Stock](#)
- Nov 14, 2017*  
[Achillion Announces Proposed Secondary Offering of Common Stock](#)
- Nov 14, 2017*  
[Achillion Reports Preliminary Proof-of-Concept With ACH-4471 for the Treatment of C3G](#)

**Upcoming Events** [ View all ]

- Feb 14, 2018 11:30 AM ET*  
[LEERINK Partners 7th Annual Global Healthcare Conference](#)

**Financial Disclosures** [ View all ]

- [Third Quarter Financial Results](#)
- Feb 23, 2017*  
[Annual Report \(10-K\)](#)
- Apr 17, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Nov 1, 2017*  
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 4, 2017*  
[Quarterly Report \(10-Q\)](#)